Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target

Deep News08-05 15:01

INNOVENT BIO (01801.HK) reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing RMB 4.3 billion, a rise of approximately 60% over the same period last year, according to a research note from Citigroup. The results outperformed market expectations.

The growth momentum is driven by the company's "dual-engine" strategy, with its comprehensive product pipeline maintaining strong performance. Key products, including Mazdutide injection, Tafolecimab injection, and Pertuzumab biosimilar, have stood out and become significant contributors to revenue growth. In the oncology segment, five tyrosine kinase inhibitors newly included in the National Reimbursement Drug List continue to see increased market penetration. Additionally, the company has partnered with Eli Lilly to successfully expand Verzenio (abemaciclib) into the breast cancer treatment field.

Citigroup views INNOVENT BIO as one of the top picks in the Chinese biotech sector, reaffirming its "Buy" rating with a target price of HK$115.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107154360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 15:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107154360","market":"fut","top_or_hot":-1,"title":"Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target","media":"Deep News","content":"<p><b>INNOVENT BIO (01801.HK)</b> reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing RMB 4.3 billion, a rise of approximately 60% over the same period last year, according to a research note from Citigroup. The results outperformed market expectations.<br><br>The growth momentum is driven by the company's \"dual-engine\" strategy, with its comprehensive product pipeline maintaining strong performance. Key products, including Mazdutide injection, Tafolecimab injection, and Pertuzumab biosimilar, have stood out and become significant contributors to revenue growth. In the oncology segment, five tyrosine kinase inhibitors newly included in the National Reimbursement Drug List continue to see increased market penetration. Additionally, the company has partnered with Eli Lilly to successfully expand Verzenio (abemaciclib) into the breast cancer treatment field.<br><br>Citigroup views <b>INNOVENT BIO</b> as one of the top picks in the Chinese biotech sector, reaffirming its \"Buy\" rating with a target price of HK$115.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-05 15:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>INNOVENT BIO (01801.HK)</b> reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing RMB 4.3 billion, a rise of approximately 60% over the same period last year, according to a research note from Citigroup. The results outperformed market expectations.<br><br>The growth momentum is driven by the company's \"dual-engine\" strategy, with its comprehensive product pipeline maintaining strong performance. Key products, including Mazdutide injection, Tafolecimab injection, and Pertuzumab biosimilar, have stood out and become significant contributors to revenue growth. In the oncology segment, five tyrosine kinase inhibitors newly included in the National Reimbursement Drug List continue to see increased market penetration. Additionally, the company has partnered with Eli Lilly to successfully expand Verzenio (abemaciclib) into the breast cancer treatment field.<br><br>Citigroup views <b>INNOVENT BIO</b> as one of the top picks in the Chinese biotech sector, reaffirming its \"Buy\" rating with a target price of HK$115.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1107154360","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107154360","pubTimestamp":1785913278,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"INNOVENT BIO (01801.HK) reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"花旗维持信达生物看涨立场，目标价115港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"KURE":1,"FTXO":1,"TFNS":1,"IYF":1,"C":1,"01801":1},"content_text":"INNOVENT BIO (01801.HK) reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing RMB 4.3 billion, a rise of approximately 60% over the same period last year, according to a research note from Citigroup. The results outperformed market expectations.The growth momentum is driven by the company's \"dual-engine\" strategy, with its comprehensive product pipeline maintaining strong performance. Key products, including Mazdutide injection, Tafolecimab injection, and Pertuzumab biosimilar, have stood out and become significant contributors to revenue growth. In the oncology segment, five tyrosine kinase inhibitors newly included in the National Reimbursement Drug List continue to see increased market penetration. Additionally, the company has partnered with Eli Lilly to successfully expand Verzenio (abemaciclib) into the breast cancer treatment field.Citigroup views INNOVENT BIO as one of the top picks in the Chinese biotech sector, reaffirming its \"Buy\" rating with a target price of HK$115.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107154360","isCrawlerRequest":true}